Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 181 to 195 of 415 results for cardiovascular disease

  1. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

    Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.

  2. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)

    Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.

  3. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

    Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.

  4. Patiromer for treating hyperkalaemia (TA623)

    Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults.

  5. Prucalopride for the treatment of chronic constipation in women (TA211)

    Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women.

  6. Romosozumab for treating severe osteoporosis (TA791)

    Evidence-based recommendations on romosozumab (EVENITY) for severe osteoporosis in people after menopause who are at high risk of fracture.

  7. Osteoarthritis in over 16s: diagnosis and management (NG226)

    This guideline covers the diagnosis, assessment and non-surgical management of osteoarthritis. It aims to improve management of osteoarthritis and the quality of life for people with osteoarthritis.

  8. Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)

    Evidence-based recommendations on avacopan (Tavneos) for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis in adults.

  9. Specialist care of newborns

    sudden infant death syndrome (SIDS) childhood leukaemia obesity cardiovascular disease in adulthood. Part of NICEimpact maternity and...

  10. Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause (IPG738)

    Evidence-based recommendations on removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause. This involves removing a small piece of ovarian tissue using keyhole surgery, freezing and storing it. After menopause starts, the tissue is thawed and transplanted under the skin of the armpit, abdomen or forearm, with the aim of producing oestrogen.

  11. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

  12. Hearing loss in adults: assessment and management (NG98)

    This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.

  13. Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.

  14. Percutaneous transluminal renal sympathetic denervation for resistant hypertension (IPG754)

    Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.

  15. Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

    Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults.